Cyclopamine Treatment Disrupts Extracellular Matrix and Alleviates Solid Stress to Improve Nanomedicine Delivery for Pancreatic Cancer.

Bo Zhang,Honglan Wang,Ting Jiang,Kai Jin,Zimiao Luo,Wei Shi,Heng Mei,Huafang Wang,Yu Hu,Zhiqing Pang,Xinguo Jiang
DOI: https://doi.org/10.1080/1061186x.2018.1452243
2018-01-01
Journal of Drug Targeting
Abstract:As one of the most intractable tumours, pancreatic ductal adenocarcinoma (PDA) has a dense extracellular matrix (ECM) which could increase solid stress within tumours to compress tumour vessels, reduce tumour perfusion and compromise nanomedicine delivery for PDA. Thus, alleviating solid stress represents a potential therapeutic target for PDA treatment. In this study, cyclopamine, a special inhibitor of the hedgehog signalling pathway which contributes a lot to ECM formation of PDA, was exploited to alleviate solid stress and improve nanomedicine delivery to PDA. Results demonstrated that cyclopamine successfully disrupted ECM and lowered solid stress within PDA, which increased functional tumour vessels and resulted in enhanced tumour perfusion as well as improved tumour nanomedicine delivery in PDA-bearing animal models. Therefore, solid stress within PDA represents a new therapeutic target for PDA treatment.
What problem does this paper attempt to address?